Immuneering (NASDAQ:IMRX) Trading Down 0.9% – Here’s Why

Immuneering Corporation (NASDAQ:IMRX)’s stock price dropped 0.9% during mid-day trading on Thursday . The company traded as low as $4.47 and last traded at $4.57. 623,957 shares traded hands during mid-day trading, an increase of 0% from the average daily volume of 621,096 shares. The stock had previously closed at $4.61.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on IMRX shares. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Needham & Company LLC upped their price target on Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Cantor Fitzgerald began coverage on Immuneering in a report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price objective on the stock. HC Wainwright reissued a “buy” rating on shares of Immuneering in a research note on Thursday, August 27th. Finally, Chardan Capital upgraded Immuneering to a “strong-buy” rating in a report on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $17.50.

Immuneering Price Performance

The company’s 50 day moving average is $4.81 and its two-hundred day moving average is $4.98. The firm has a market cap of $276.26 million, a P/E ratio of -4.11 and a beta of 0.40.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). Research analysts predict that Immuneering Corporation will post -1.09 EPS for the current year.

Hedge Funds Weigh In On Immuneering

A number of hedge funds have recently made changes to their positions in the business. PVG Asset Management Corp acquired a new stake in Immuneering during the first quarter valued at approximately $773,000. Empery Asset Management LP acquired a new position in shares of Immuneering in the 4th quarter worth approximately $17,601,000. Blue Owl Capital Holdings LP raised its holdings in shares of Immuneering by 20.9% in the 4th quarter. Blue Owl Capital Holdings LP now owns 665,000 shares of the company’s stock worth $4,376,000 after buying an additional 115,000 shares in the last quarter. 683 Capital Management LLC bought a new position in shares of Immuneering during the 4th quarter worth approximately $992,000. Finally, DCF Advisers LLC bought a new position in shares of Immuneering during the 4th quarter worth approximately $1,415,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.